WHO criteria should be used for classification of anovulation. 
Diagnosing PCOS should be performed by using the Rotterdam criteria.

Other mimics, such as thyroid disease, prolactin excess, and congenital adrenal hyperplasia (21-hydroxylase deficiency),should be routinely excluded.B
Rare causes of similar symptoms, such as Cushing’s syndrome, androgen secreting tumor, or steroid abuse, should be selectively excluded.B
Women with PCOS should not undergo routine screening with ultrasound or biopsy for endometrial cancer. C
Women with PCOS should undergo routine screening for dysglycemia with an oral glucose tolerance test or a glycohemoglobin level.A
Women with PCOS should undergo routine screening with a fasting lipid profile. A
Women with PCOS should be selectively screened for sleep disorders and liver disease. C
Other infertility factors should be considered in couples presenting with infertility presumed secondary to female PCOS-related anovulation.A

In anovulatory patients, FSH, LH, and estradiol should be determined during the initial workup. To rule out other pathologies,prolactin, TSH, and early morning cortisol should be measured too.B
In anovulatory patients, a thorough history should be taken focusing on lifestyle habits (extreme exercise, poor caloric intake, and obesity), signs of other endocrinopathies (i.e., hypothalamic or pituitary lesions, hyperprolactinemia, hypothyroidism, and hyperthyroidism). The screening history should also focus on a family history of irregular cycles, HA, or early menopause along with a family history of autoimmune disorders (e.g., thyroid disorders, diabetes, Addison’s disease, vitiligo, systemic lupus,
rheumatoid arthritis, celiac disease), fragile X syndrome, or intellectual disability.B
The physical examination should focus on body habitus, evidence of normal secondary sexual characteristics, hirsutism, and alopecia as well as evidence of vaginal atrophy secondary to hypo-estrogenism.B
MRI might aid in the diagnosis of Kallmann syndrome and is mandatory in cases with multiple endocrinopathies to rule out tumors in the pituitary or midbrain regions.B
Gn-RH testing is not cost-effective and not recommended. IGF-1 measurements are only recommended in WHO 1 patients without any sigs of pubertal development.C
Accurate olfactory phenotyping in IHH subjects can inform the pathophysiology of this condition and guide genetic testing. C
Renal ultrasound examination is recommended to patients with syndromic IHH, such as Kallmann syndrome, independent of the genetic basis.C
Bone mineral density of the lumbar spine, femoral neck, and hip is recommended at the initial diagnosis of HH and after 1 to 2 years of sex steroid therapy in hypogonadal patients with osteoporosis or low trauma fracture.C
PCOS should be diagnosed according to the Rotterdam consensus. B
Clinical hyperandrogenism (HA) should be assessed using the Ferriman-Gallwey score. Biochemical HA should preferably be assessed according to the available assay (either LCM/S or RIA assays).B
Adolescent PCOS is diagnosed if all three Rotterdam consensus characteristics of PCOS are present. C
In postmenopausal women, the diagnosis is impossible to make but should be considered in women with a clear-cut history of irregular menstrual periods and signs of hyperandrogenism, such as hirsutism.C
The diagnosis should be confirmed by obtaining two consecutive FSH measurements revealing levels in the menopausal range (>40 IU/L) at least 1 month apart in the setting of 6 months of amenorrhea.B
Women with POI should be screened for X chromosome aberrations and for FMR1 gene (pre) mutations. B
Women with POI should also be screened for auto-antibodies against adrenal, thyroid tissue, and thyroid stimulating hormone receptors and ovarian tissue.B
Measurement of AMH or AFC is not routinely recommended for women with POI. C
BMD measurements are not recommended in women with POI who have been treated with HRT since the time of diagnosis.